菲卓替尼(Fedratinib Hydrochloride) - 药物靶点：FLT3 x JAK2_在研适应症：原发性血小板增多症后骨髓纤维化，真性红细胞增多症后骨髓纤维化，原发性骨髓纤维化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

FEDR、Fedratinib、INREBIC

+ [4]

靶点

FLT3 x JAK2

作用方式

抑制剂

作用机制

FLT3抑制剂(酪氨酸蛋白激酶受体FLT3抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病其他疾病

在研适应症

原发性血小板增多症后骨髓纤维化真性红细胞增多症后骨髓纤维化原发性骨髓纤维化+ [8]

非在研适应症

晚期恶性实体瘤急性转化期慢性粒细胞性白血病肝损伤+ [3]

原研机构

TargeGen, Inc.

在研机构

Bristol Myers Squibb Co.

Celgene Corp.Bristol-Myers Squibb Pharma EEIG

+ [2]

非在研机构

TargeGen, Inc.

权益机构

Impact Biomedicines, Inc.

Celgene Corp.

Sanofi

最高研发阶段批准上市

首次获批日期

美国 (2019-08-16),

骨髓纤维化真性红细胞增多症原发性血小板增多症

最高研发阶段(中国)临床3期

特殊审评孤儿药 (美国)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

分子式C27H40Cl2N6O4S

InChIKeyQAFZLTVOFJHYDF-UHFFFAOYSA-N

CAS号1374744-69-0

关联

30

项与菲卓替尼相关的临床试验

NCT05883904

/ RecruitingN/AIIT

Observational Study Protocol REALFed - Real World Evidence of Fedratinib Effectiveness in Myelofibrosis

This is a multicenter prospective and retrospective observational clinical study in patients with primary or post polycythemia vera or post essential thrombocythemia myelofibrosis to test the efficacy of fedratinib in the rea world. Participants will be managed according to the clinical practice of the participating Center. All Centers will be Italian Hematology Units belonging to the GIMEMA Organization in Italy.

开始日期2024-01-29

申办/合作机构

Gruppo Italiano Malattie EMatologiche dell'Adulto

NCT06073847

/ RecruitingN/A

Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis

The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and/or are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review & Assessment Service.

开始日期2023-06-13

申办/合作机构

Bristol Myers Squibb Co.

ISRCTN88102629

/ Recruiting临床2期IIT

A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis

开始日期2022-09-12

申办/合作机构

University of Birmingham

100 项与菲卓替尼相关的临床结果

登录后查看更多信息

100 项与菲卓替尼相关的转化医学

登录后查看更多信息

100 项与菲卓替尼相关的专利（医药）

登录后查看更多信息

556

项与菲卓替尼相关的文献（医药）

2025-04-22·Blood Advances

Fedratinib in 2025 and beyond: indications and future applications

Review

作者: Coltoff, Alexander ; Mascarenhas, John

Abstract:

Dysregulated JAK/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomatic myelofibrosis. Fedratinib has characteristics that distinguish it from other commercially available JAK inhibitors, such as its preferential inhibition of JAK2 and its inhibitory effects on kinases such as Fms-like tyrosine kinase 3 and BRD4. Fedratinib is most often used in the second-line setting after intolerance or resistance to other JAK inhibitors, but there is substantial evidence that it is an effective first-line option in the appropriate patient population. Prevention and early treatment of fedratinib-related gastrointestinal toxicity is key to maintaining adequate drug exposure, and clinicians must remain vigilant for Wernicke encephalopathy during treatment. Fedratinib’s JAK2 selectivity and kinome profile make it an appealing agent for alternative indications, such as myelodysplastic/myeloproliferative neoplasms and maintenance after bone marrow transplantation, which are under active investigation.

2025-04-17·BLOOD

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Article

作者: Chifotides, Helen T. ; Masarova, Lucia

Abstract:

The advent of Janus kinase inhibitors (JAKis) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manifestations. Four JAKis have been approved for intermediate or high-risk MF, in the United States. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011, transformed the landscape of MF by markedly controlling splenomegaly and constitutional symptoms, improving patients’ quality of life, and prolonging survival. Fedratinib, the second approved JAKi, is preferred in the second-line setting. Ruxolitinib and fedratinib can cause myelosuppression and are recommended for patients with the myeloproliferative phenotype. The approval of 2 less-myelosuppressive JAKis, pacritinib and momelotinib, provided essential treatment options for patients with severe thrombocytopenia and anemia, respectively. Momelotinib and pacritinib are potent activin A receptor, type 1 inhibitors with consequent significant benefits for patients with anemia. Transfusion independence was achieved with momelotinib in patients who were severely anemic, and the association of transfusion independence with prolonged overall survival was demonstrated. Judicious treatment decisions regarding JAKis can be made with in-depth understanding of the pivotal clinical trials that evaluated JAKis and their therapeutic attributes and should be guided by the dominant clinical manifestations and the type/degree of cytopenia(s) (myeloproliferative/cytopenic phenotypes). This article reviews our clinical approach to treatment with JAKis and their sequencing in patients with MF by presenting 3 clinical vignettes.

2025-04-01·Clinical Lymphoma Myeloma & Leukemia

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis

Review

作者: Hunter, Anthony M ; Vale, Colin A ; Hochman, Michael J

Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by myeloproliferation, bone marrow fibrosis, splenomegaly, and constitutional symptoms related to pro-inflammatory cytokine signaling. Biologically, MF is characterized by constitutive activation of JAK-STAT signaling; accordingly, JAK inhibitors have been rationally developed to treat MF. Following the initial approval of ruxolitinib in 2011, three additional agents have been approved: fedratinib, pacritinib, and momelotinib. As these therapies are noncurative, allogeneic stem cell transplantation remains a key treatment modality and patients with MF who are deemed candidates should be referred to a transplant center. This potentially curative but toxic approach is typically reserved for patients with higher-risk disease, and JAK inhibitors are recommended in the pretransplant setting. JAK inhibitors have proven effective at managing splenomegaly and constitutional symptoms and should be started early in the disease course in patients presenting with these clinical manifestations; asymptomatic patients may initially be followed with close surveillance. Drug-related myelosuppression has been a challenge with initial JAK inhibitors, particularly in patients presenting with a cytopenic phenotype. However, newer agents, namely pacritinib and momelotinib, have proven more effective in this setting and are approved for patients with significant thrombocytopenia and anemia, respectively. Resistance or disease progression is clinically challenging and may be defined by several possible events, such as increasing splenomegaly or progression to accelerated or blast phase disease. However, with multiple JAK inhibitors now approved, sequencing of these agents appears poised to improve outcomes. Additionally, novel JAK inhibitors and JAK inhibitor-based combinations are in clinical development.

67

项与菲卓替尼相关的新闻（医药）

2025-03-12

·微信

AJH丨梅奥经验：脾切除术在JAK2抑制剂治疗的骨髓纤维化患者中的结果

点击蓝字关注我们编者按骨髓纤维化（MF）是一种以脾脏肿大和骨髓功能衰竭为特征的骨髓增殖性肿瘤。JAK2V617F突变的发现和JAK2抑制剂（JAKi）的开发彻底改变了MF的治疗格局。然而，JAKi治疗的益处通常是短暂的，许多患者最终会因耐药而停药。为此，梅奥诊所Naseema Gangat教授等探讨了脾切除术在JAK2抑制剂治疗的骨髓纤维化患者中的应用，并于近期发表于American Journal of Hematology。本文特整理研究主要内容，以飨读者。骨髓纤维化（MF）是一种以脾脏肿大和骨髓功能衰竭为特征的骨髓增殖性肿瘤。JAK2V617F突变的发现和JAK2抑制剂（JAKi）的开发彻底改变了MF的治疗格局。目前，美国食品药品监督管理局（FDA）已批准四种JAKi用于MF的治疗：芦可替尼（Ruxolitinib）、菲卓替尼（Fedratinib）、帕瑞替尼（Pacritinib）和莫洛替尼（Momelotinib）。这些药物能够有效缓解脾脏肿大和全身症状。然而，JAKi治疗的益处通常是短暂的，许多患者最终会因耐药而停药。对于JAKi耐药的患者，脾切除术或脾脏放疗通常被建议作为异体造血干细胞移植（ASCT）的桥梁。本研究回顾性分析了梅奥诊所34例接受JAKi治疗后进行脾切除术的MF患者。纳入标准包括：（1）根据国际共识分类诊断为MF；（2）有JAKi治疗记录并随后进行了脾切除术；（3）有术前和术后的详细信息。最终纳入34例患者，其中29例接受开腹脾切除术，5例接受腹腔镜脾切除术。患者特征 34例MF患者中，原发性MF（PMF）18例，真性红细胞增多症后MF （post-PV MF）15例，原发性血小板增多症后MF（post-ET MF）1例。中位年龄为63岁，59%为男性，中位脾脏长度为25.1厘米（范围14.7-36厘米）。21例（62%）检测到JAK2V617F突变，9例（26%）检测到CALR突变，1例（3%）检测到MPL突变，3例（9%）为三阴性。26例（76%）接受过一种JAKi治疗，6例（18%）接受过两种JAKi治疗，2例（6%）接受过三种JAKi治疗。具体JAKi包括芦可替尼（Ruxolitinib，79%）、莫洛替尼（Momelotinib，15%）、菲卓替尼（Fedratinib，9%）、帕瑞替尼（Pacritinib，9%）和BMS 911543（15%）。术后并发症 21例（62%）患者报告了术后并发症，包括重大出血（29%）、血栓形成（26%）和其他并发症（感染、肾损伤、气胸）。PMF与post-PV/ET MF患者并发症发生率之间无统计学差异（78% vs. 50%，P=0.09），使用一种与两种或更多JAKi患者并发症发生率之间亦无统计学差异（71% vs. 50%，P=0.29），停药与继续使用JAKi患者并发症发生率之间也无统计学差异（64% vs. 61%，P=0.88）。生存率和移植结果脾切除术后中位随访1.7年（范围0.01-10.2年），15例（44%）患者死亡。脾切除术后中位生存期为4.3年，30天和60天死亡率分别为6%和15%。 △脾切除术后患者生存情况 14例患者在接受脾切除术后准备移植，其中12例（86%）成功桥接至ASCT，中位时间为3个月（范围1.5-26个月）。移植患者的中位生存期未达到，而非移植患者为2.6年（5年生存率65% vs. 22%，P=0.02）。移植后中位随访2.6年（范围0.3-9.8年），7例（58%）患者仍存活且完全缓解，2例（17%）复发，3例（25%）死于感染和移植物抗宿主病。 △脾切除术后移植或未移植患者生存情况血液学改善 22例未接受ASCT的患者中，10例（45%）在脾切除术时有输血依赖性贫血，其中5例（50%）在术后至少12周内不再需要输血，中位输血独立反应持续时间为2.8年（范围0.3-7.1年）。5例基线血小板计数低于50×10^9/L的患者中，4例（80%）在术后3个月内血小板计数超过100×10^9/L，中位血小板计数为170×10^9/L（范围119-279×10^9/L）。 △脾切除术、脾切除术后 6 周至 3 个月和 1 年的中位血细胞计数结论脾切除术在JAKi治疗后的MF患者中具有重要的治疗价值，既可作为桥接至ASCT的手段，也可作为改善输血依赖性贫血和血小板减少症的姑息治疗策略。尽管术后并发症发生率较高，但大多数患者能够成功桥接至ASCT，并在移植后长期存活且完全缓解。未来的研究需要进一步确定术后并发症的预测因素，以指导管理策略，并确定脾切除术后和围移植期JAKi使用的最佳方法。参考文献： Carey P, Pardanani A, Starlinger P, Tefferi A, Gangat N. Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases. Am J Hematol. 2025 Mar;100(3):527-530. doi: 10.1002/ajh.27570. Epub 2024 Dec 26. PMID: 39723660. （来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果

2025-02-20

·药筛

专利未到，首仿已获批

今天继续推荐关注品种：磷酸芦可替尼片。原研全球市场销售一路高歌猛进，2024年超过50亿美元，还有增长潜力。国内市场，原研诺华2017年进口，2019年进入医保目录，目前独家在售。医院市场年销售额超过5亿，加上院外市场，总规模约10亿元。原研国内核心专利2026年到期，国内已有多个企业申报仿制。成都苑东首家报产获批上市，但不能上市销售。正大天晴、重庆华森等，多个企业申报，竞争激烈以下是产品简介，由摩熵医药AI生成。磷酸芦可替尼片（Ruxolitinib Phosphate）详细分析一、药物基本信息通用名：磷酸芦可替尼（Ruxolitinib Phosphate）商品名：捷恪卫（Jakavi，美国商品名Jakafi）靶点：JAK1/JAK2抑制剂（选择性抑制Janus激酶通路）适应症：中高危骨髓纤维化（MF）；真性红细胞增多症（PV）对羟基脲耐药或不耐受；急性移植物抗宿主病（GVHD）；特应性皮炎（部分国家获批）研发公司：由Incyte Corporation研发，诺华（Novartis）负责美国以外市场商业化。二、作用机制与药理学特点 JAK-STAT通路抑制：芦可替尼通过抑制JAK1和JAK2激酶，阻断促炎细胞因子（如IL-6、IFN-γ）和促增殖信号（如EPO、TPO）的传导。在骨髓纤维化中，抑制异常活化的JAK2 V617F突变信号，减少炎症因子释放和髓外造血。选择性优势：对JAK2的选择性高于JAK3（避免过度免疫抑制），但对JAK1的抑制可能增加感染风险。三、药代动力学（PK/PD）吸收：口服生物利用度约95%，达峰时间1-2小时，食物对吸收无显著影响。代谢：主要经CYP3A4代谢，次要经CYP2C9。半衰期：约3小时，需每日两次给药。排泄：74%经尿液（主要为代谢物），22%经粪便。特殊人群：肝肾功能不全者需调整剂量（如Child-Pugh B/C患者剂量减半）。四、临床疗效数据骨髓纤维化（MF）： 41.9%患者脾脏体积缩小≥35%（vs. 0.7%安慰剂组）； 45.9%患者总症状评分改善≥50%（vs. 5.3%安慰剂组）。 COMFORT-I/II试验（III期）：生存获益：5年随访显示芦可替尼组生存期显著延长（HR=0.69）。真性红细胞增多症（PV）： 21%患者达到完全血液学缓解（vs. 1%对照组）； 60%患者无需放血治疗（vs. 20%对照组）。 RESPONSE试验： GVHD： REACH试验：芦可替尼治疗激素难治性急性GVHD，总缓解率（ORR）达57%。五、安全性及不良反应常见不良反应：血液系统：贫血（44%）、血小板减少（38%）、中性粒细胞减少（16%）。感染：带状疱疹（7%）、尿路感染（10%）。其他：头晕、头痛、血脂升高。黑框警告：严重感染（结核、真菌、细菌性肺炎等）；恶性肿瘤风险（如淋巴瘤、非黑色素瘤皮肤癌）；血栓事件（深静脉血栓、肺栓塞）。六、药物政策与市场表现国内现状： 2017年在中国获批骨髓纤维化适应症，2020年进入国家医保（乙类）。价格：约500元/5mg/片（医保后自付比例约30%）。全球市场： 2022年全球销售额：Jakafi（美国）20.3亿美元，Jakavi（海外）14.6亿美元。核心竞争产品：Fedratinib（JAK2抑制剂）、Momelotinib（JAK1/2/ACVR1抑制剂）。七、研发进展与未来方向适应症拓展：白癜风：III期试验显示52周后面部复色率≥75%的患者达30%；特应性皮炎：欧盟已批准，美国处于III期临床。联合疗法：与BCL-2抑制剂（Venetoclax）联用探索骨髓纤维化治疗；与PD-1抑制剂联用于实体瘤（早期临床）。用摩熵药筛小程序，快速查询产品申报进展！

专利到期临床3期

2024-12-20

·PRNewswire

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.1 PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid lineage with exuberant red cell production and increased release of pro-inflammatory cytokines. More than 95% of PV patients harbor the JAK2 V617F gain-of-function mutation leading to aberrant JAK2 production.2 Inhibiting JAK2 acts to suppress hematopoiesis, consequently reducing red blood cell, neutrophil, platelet, and lymphocyte production. JAK2 inhibitors have been shown to be efficacious in treating various JAK-dependent hematologic malignancies, including the treatment of PV. By selective reduction of JAK2 levels, the ASO VGT-1849A has the potential to reduce JAK2V617F-driven pathogenic signaling, ultimately suppressing the malignant proliferation and survival of hematopoietic cells. Currently available small molecule inhibitors targeting the JAK2 protein kinase, such as Jakafi®, Inrebic®, Ojjaara®, and Vonjo®, lack sole selectivity for the target protein, which can result in off target effects. The adverse side effects that may occur from JAK inhibition emphasize the importance of selectively targeting JAK2 while avoiding inhibition of other JAK family members. By specifically targeting JAK2, Vanda seeks to reduce the risk of infection and toxic effects that are seen with inhibitors also blocking JAK1, JAK3, TYK2, or other kinases outside of the JAK family. If approved, VGT-1849A could offer targeted efficacy with an improved safety profile and convenient dosing. "This orphan designation for VGT-1849A is an important milestone in precision medicine-based therapeutics in the space of hematological malignancies. This milestone marks the second precision medicine therapeutic for Vanda following the development of VCA-894A for Charcot-Marie-Tooth3 that is expected to begin clinical testing in the coming months," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. VGT-1849A is a novel ASO treatment candidate for PV and other JAK2-driven hematologic malignancies. By selectively targeting JAK2, VGT-1849A reduces downstream signaling and JAK2V617F-driven autonomous cell proliferation, without any off-target kinase effects. The ability of VGT-1849A to reduce JAK2 activity may alleviate the disease burden that patients with PV face with a favorable safety profile, resulting in a higher quality of life for patients. Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical conditions and provides benefits to drug developers. References: Grunwald, M. R.; Stein, B. L.; Boccia, R. V.; Oh, S. T.; Paranagama, D.; Parasuraman, S.; Colucci, P.; Mesa, R. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk 2018, 18 (12), 788-795.e2. . P. Gou, W. Zhang, and S. Giraudier, "Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms," Myeloproliferative Neoplasms. Int. J. Mol. Sci, vol. 2022, p. 1013, 2022, S. Smieszek, C. Tyner, A. Kaden, C. Johnson, C. Polymeropoulos, G. Birznieks, M. Polymeropoulos. Potential treatment for CMT2S caused by IGHMBP2 cryptic splice variant, with ASO based therapeutic [abstract]. Mov Disord. 2023; 38 (suppl 1). . About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. About VGT-1849A VGT-1849A is an antisense oligonucleotide (ASO) that selectively targets JAK2, reducing increased activity of JAK2 that may cause hematologic malignancies. ASOs have broad applicability in addressing a number of disorders caused by genetic variants. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this press release, including, but not limited to statements regarding the estimated prevalence of PV, the potential therapeutic effects of VGT-1849A, the timing of the initiation of clinical testing of VCA-894A and the potential benefits of VGT-1849A, are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the accuracy of the reporting and diagnosis of PV cases, the ability of VGT-1849A to safely and effectively treat PV, Vanda's ability to begin clinical testing of VCA-894A during the specified timeframe and Vanda's ability to successfully complete the clinical development of, and obtain regulatory approval for, VGT-1849A in the treatment of PV. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at . All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] SOURCE Vanda Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药寡核苷酸

100 项与菲卓替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	菲卓替尼	L01XE57	DB12500

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性血小板增多症后骨髓纤维化	欧盟	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性血小板增多症后骨髓纤维化	冰岛	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性血小板增多症后骨髓纤维化	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性血小板增多症后骨髓纤维化	挪威	Bristol-Myers Squibb Pharma EEIG	2021-02-08
真性红细胞增多症后骨髓纤维化	欧盟	Bristol-Myers Squibb Pharma EEIG	2021-02-08
真性红细胞增多症后骨髓纤维化	冰岛	Bristol-Myers Squibb Pharma EEIG	2021-02-08
真性红细胞增多症后骨髓纤维化	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2021-02-08
真性红细胞增多症后骨髓纤维化	挪威	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性骨髓纤维化	欧盟	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性骨髓纤维化	冰岛	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性骨髓纤维化	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2021-02-08
原发性骨髓纤维化	挪威	Bristol-Myers Squibb Pharma EEIG	2021-02-08
脾肿大	欧盟	Bristol-Myers Squibb Pharma EEIG	2021-02-08
脾肿大	冰岛	Bristol-Myers Squibb Pharma EEIG	2021-02-08
脾肿大	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2021-02-08
脾肿大	挪威	Bristol-Myers Squibb Pharma EEIG	2021-02-08
骨髓纤维化	美国	Bristol Myers Squibb Co.	2019-08-16
真性红细胞增多症	美国	Bristol Myers Squibb Co.	2019-08-16
原发性血小板增多症	美国	Bristol Myers Squibb Co.	2019-08-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血液肿瘤	临床3期	美国	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	澳大利亚	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	奥地利	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	比利时	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	巴西	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	加拿大	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	法国	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	德国	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	匈牙利	Bristol Myers Squibb Co.	2011-12-01
血液肿瘤	临床3期	爱尔兰	Bristol Myers Squibb Co.	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03952039 (FREEDOM2, Pubmed \| Lancet Haematol) 人工标引	临床3期	骨髓纤维化二线	201	Fedratinib 400 mg per day	衊獵鬱壓廠鹽願醖壓鹹(醖願淵蓋繭遞鹽觸鹽餘) = 獵願憲繭膚鏇糧顧積構夢鏇鹹蓋網觸廠淵鑰積 (構衊窪壓鑰壓艱醖選鬱 ) 更多	积极	2024-09-01
				Best Available Therapy (BAT)	衊獵鬱壓廠鹽願醖壓鹹(醖願淵蓋繭遞鹽觸鹽餘) = 鬱夢餘鑰範憲淵選觸觸夢鏇鹹蓋網觸廠淵鑰積 (構衊窪壓鑰壓艱醖選鬱 ) 更多
NCT03755518 (FREEDOM, Pubmed \| Leuk Lymphoma)	临床3期	骨髓纤维化	38	Fedratinib	製繭齋糧鏇壓選夢範艱(憲窪鬱膚糧淵襯觸糧淵) = 窪顧繭襯膚積範鬱築築膚齋鑰蓋繭築顧憲鹹淵 (齋衊築顧蓋艱範鏇醖築, 12.5 ~ 43.3) 更多	积极	2024-07-28
NCT03952039 (FREEDOM2, EHA2024) 人工标引	临床3期	骨髓纤维化二线	201	Fedratinib 400mg daily	餘鏇襯鏇餘鑰鹹網膚遞(淵網製遞鑰製襯製簾蓋) = 製艱鑰網獵齋選窪遞襯繭鏇選廠網觸築蓋齋觸 (遞願鏇醖鏇構醖鏇鹹鑰 ) 更多	积极	2024-05-14
				Best Available Therapy (BAT)	餘鏇襯鏇餘鑰鹹網膚遞(淵網製遞鑰製襯製簾蓋) = 襯鏇膚糧積範夢製艱憲繭鏇選廠網觸築蓋齋觸 (遞願鏇醖鏇構醖鏇鹹鑰 ) 更多
Tandem Meetings ASTCT and CIBMTR2024	N/A	骨髓纤维化	18	Fedratinib 400 mg once daily	憲繭餘憲鹽淵鏇積築醖(製觸醖窪範齋製積範廠) = n=4 (22.2%) deaths were recorded as of May 2023. Two of the 4 deaths were related to MF and both patients had disease transformation to blast phase MPN before HSCT. A median duration of 14.5 months elapsed between FEDR initiation and death among these 4 patients 選顧觸簾夢淵遞願積艱 (餘襯壓鑰憲壓鬱繭遞壓 ) 更多	积极	2024-02-01
NCT03952039 (FREEDOM2, CTgov)	临床3期	原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 \| 原发性骨髓纤维化	202	Best Available Therapy (BAT)	築膚願網選鹽艱遞範鑰 = 願艱獵窪糧選憲鬱觸觸壓鑰鏇鑰願積觸鹽願餘 (構艱廠壓範願襯獵蓋壓, 鬱鑰網鏇醖網選製艱淵 ~ 選襯簾積齋遞積襯構鬱) 更多	-	2024-01-30
NCT04817007 (CA011-023, ASH2023)	临床1/2期	原发性骨髓纤维化	40	BMS-986158+Ruxolitinib	窪製鬱觸範選鏇壓淵壓(壓製窪夢遞選蓋壓膚繭) = 鏇夢餘鏇醖膚衊製鏇膚餘構積膚窪艱糧醖廠鏇 (願鏇簾鑰餘鑰繭願壓鬱 )	-	2023-12-10
				BMS-986158+Fedratinib	窪製鬱觸範選鏇壓淵壓(壓製窪夢遞選蓋壓膚繭) = 繭選蓋鑰餘鬱鹽築構選餘構積膚窪艱糧醖廠鏇 (願鏇簾鑰餘鑰繭願壓鬱 )
NCT03952039 (FREEDOM2, ASH2023)	临床3期	骨髓纤维化	201	Fedratinib 400 mg/day	淵觸繭憲願鬱積鏇願齋(觸憲繭繭繭簾製願憲餘) = 網簾選鑰網憲遞膚構鏇憲衊廠顧齋憲鹹衊製鹽 (壓膚鏇齋夢窪膚壓遞遞 ) 更多	积极	2023-12-10
				Best Available Therapy (BAT)	淵觸繭憲願鬱積鏇願齋(觸憲繭繭繭簾製願憲餘) = 構鹹夢獵獵鹽鹽鬱壓鬱憲衊廠顧齋憲鹹衊製鹽 (壓膚鏇齋夢窪膚壓遞遞 ) 更多
ASH2023	N/A	原发性骨髓纤维化	58	Fedratinib	憲製鑰遞壓醖簾製積鹽(餘範夢鬱積糧醖網淵衊) = 鏇顧鏇願夢餘築鏇顧觸醖蓋窪網襯衊鹹醖築鏇 (觸憲繭壓繭餘繭鹹築網 )	-	2023-12-09
NCT05177211 (ASH2023)	临床2期	慢性中性粒细胞白血病 \| 骨髓增生性疾病	10	Fedratinib	鹽襯淵製積蓋簾鹽獵顧(醖鑰築築鹹鬱夢網獵齋) = 襯衊糧範鑰艱廠憲遞糧選壓艱製糧獵鬱鏇鑰廠 (糧鹹鑰築醖構鹹鬱鑰膚 ) 更多	-	2023-12-09
ASH2023	N/A	二线	-	Ruxolitinib	鬱簾壓遞鹽膚鬱齋製製(壓憲鹹齋壓襯遞蓋醖艱) = 繭襯鹽醖窪鏇製鏇獵範窪糧壓憲鏇鏇襯齋衊襯 (淵繭蓋遞鑰積膚艱簾繭 ) 更多	-	2023-12-09
				Fedratinib	鬱簾壓遞鹽膚鬱齋製製(壓憲鹹齋壓襯遞蓋醖艱) = 繭餘構繭膚夢膚鹽鹹遞窪糧壓憲鏇鏇襯齋衊襯 (淵繭蓋遞鑰積膚艱簾繭 )